Company: XAIR
Filing Date: 2025-06-20
Form Type: 10-K
Source: 0001641172-25-015750
Chunk: 722

Company: Beyond Air, Inc.
Filing Date: 2025-06-20
Form: 10-K
Item: Item 1
Chunk 722
---
224,139  
    $0.14  
     -  
     - 
  
    Exercised 
     -  
     -  
     -  
     - 
  
    Forfeited 
     -  
     -  
     -  
                 - 
  
    Options outstanding as of March 31, 2025 
     1,224,139  
    $0.14  
     9.0  
    $- 

    Exercisable as of March 31, 2025 
     306,035  
    $0.14  
     9.0  
    $- 

As of March 31, 2025, the Company had unrecognized
stock-based compensation expense for the stock options in the 2023 NNOS Plan of approximately $0.1 million which is expected to be expensed
over the weighted average remaining service period of 1.5 years.

    F-23

BEYOND AIR, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 4 STOCKHOLDERS’ EQUITY (continued)

The following was utilized to calculate the fair value
of options on the date of grant:

SCHEDULE OF FAIR VALUE OF OPTION 

    March 31, 2025

    March 31, 2024

    Risk -free interest rate

    3.6-4.4
    %

    3.5-4.9
    %
  
    Expected volatility (Beyond Air)

    83.6-89.9
    %

    81.4-82.7 
    %
  
    Expected volatility (Beyond Cancer)

    -
    %

    104.3 - 106.2
    %
  
    Expected volatility (NeuroNos)

    95.0
    %

    -
    %
  
    Dividend yield

    0
    %

    0
    %
  
    Expected terms (in years)

    6.25

    6.25

The Company determined
the fair value per share of Beyond Cancer’s common stock to be $5.50
in fiscal years 2024 based on a third-party valuation.

The Company determined
that the fair value per share of NeuroNos’ common stock to be $0.14
at